A billion dollars can change the fight against cancer forever. Thanks to the generosity of our donors, OHSU’s Knight Cancer Institute is launching the first grand-scale program to radically improve early detection of lethal cancers.
With $1 billion in new funding, OHSU will begin fast-track recruitment of 250 to 300 scientists and physician investigators, including about 25 of the world’s top researchers.
OHSU is already accelerating the design and construction of a cancer research facility and the cancer care clinics needed to support these recruits and to house the clinical trials that will move promising new tests and treatments from the lab to patients more quickly.
These leading scientists will come to Oregon to unite behind a single, powerful vision to transform cancer care. Here, they will be given the financial support they need to ensure they can focus on research rather than seeking and administering grants.
Our goal is to vastly improve cancer survivorship and reduce the risk of unnecessary treatments by transforming how lethal forms of the disease are detected. Watch this video to learn why solving the problem of early detection will save countless lives.
Our plan expands upon the Knight Cancer Institute’s strengths in pioneering targeted cancer treatments. Institute director Brian Druker, M.D., conducted the breakthrough research that led to development of Gleevec®, the first once-a-day cancer pill that proved it was possible to treat just the malfunctioning genes that cause the disease without harming healthy cells. Adding research that expands the understanding of the biological precursors to cancer will help catch the disease in its very earliest stages when precision therapies can be most effective. Ultimately this research could lead to molecularly based prevention.
“Though we’ve made huge strides in the sophistication of cancer treatments, the same can’t be said of detection tools, which haven’t changed in decades. Today too many patients die or have to suffer through debilitating treatments because their disease is caught too late. No one else is focused on this problem in a meaningful way and we are committed to filling that gap,” Druker says. “We are thankful to everyone who is making this goal a reality.”